These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1391 related items for PubMed ID: 19007835

  • 1. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
    Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P.
    Vaccine; 2009 Jan 14; 27(3):446-53. PubMed ID: 19007835
    [Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
    Goh P, Lim FS, Han HH, Willems P.
    Infection; 2007 Oct 14; 35(5):326-33. PubMed ID: 17710370
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
    Halperin SA, Ferrera G, Scheifele D, Predy G, Stella G, Cuccia M, Douha M, Willems P.
    Vaccine; 2009 May 05; 27(20):2701-6. PubMed ID: 19428882
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
    Vesikari T, Baer M, Willems P.
    Pediatr Infect Dis J; 2007 Feb 05; 26(2):153-8. PubMed ID: 17259879
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 05; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 6. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ, Consistency Lot Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Jul 05; 25(7):615-22. PubMed ID: 16804432
    [Abstract] [Full Text] [Related]

  • 7. A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.
    Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P.
    Vaccine; 2009 Nov 05; 27(47):6504-11. PubMed ID: 19665608
    [Abstract] [Full Text] [Related]

  • 8. Combination measles, mumps, rubella and varicella vaccine.
    Arbeter AM, Baker L, Starr SE, Levine BL, Books E, Plotkin SA.
    Pediatrics; 1986 Oct 05; 78(4 Pt 2):742-7. PubMed ID: 3763291
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P.
    Pediatr Infect Dis J; 2006 Jan 05; 25(1):12-8. PubMed ID: 16395096
    [Abstract] [Full Text] [Related]

  • 10. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M, Broder KR, Temte JL, Snider DE, Seward JF, Centers for Disease Control and Prevention (CDC).
    MMWR Recomm Rep; 2010 May 07; 59(RR-3):1-12. PubMed ID: 20448530
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
    Shinefield H, Black S, Thear M, Coury D, Reisinger K, Rothstein E, Xu J, Hartzel J, Evans B, Digilio L, Schödel F, Brown ML, Kuter B, 013 Study Group for ProQuad.
    Pediatr Infect Dis J; 2006 Apr 07; 25(4):287-92. PubMed ID: 16567978
    [Abstract] [Full Text] [Related]

  • 12. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM, Baker L, Starr SE, Plotkin SA.
    Dev Biol Stand; 1986 Apr 07; 65():89-93. PubMed ID: 3030864
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH, Hirai HW, Tsoi KK.
    Expert Rev Vaccines; 2015 Apr 07; 14(8):1149-57. PubMed ID: 26081133
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T, Bernstein DI, Block SL, Hilty M, Keyserling HL, Marchant C, Marshall H, Richmond P, Yogev R, Cordova J, Cho I, Mendelman PM, LAIV Study Group.
    Pediatrics; 2008 Mar 07; 121(3):508-16. PubMed ID: 18310199
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of a varicella vaccine, Okavax, and a trivalent measles, mumps and rubella vaccine, MMR-II, administered concomitantly in healthy Filipino children aged 12-24 months.
    Gatchalian S, Leboulleux D, Desauziers E, Bermal N, Borja-Tabora C.
    Southeast Asian J Trop Med Public Health; 2003 Sep 07; 34(3):589-97. PubMed ID: 15115135
    [Abstract] [Full Text] [Related]

  • 16. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
    Reisinger KS, Brown ML, Xu J, Sullivan BJ, Marshall GS, Nauert B, Matson DO, Silas PE, Schödel F, Gress JO, Kuter BJ, Protocol 014 Study Group for ProQuad.
    Pediatrics; 2006 Feb 07; 117(2):265-72. PubMed ID: 16452343
    [Abstract] [Full Text] [Related]

  • 17. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 18. Immunogenicity and safety of measles-mumps-rubella, varicella and Haemophilus influenzae type b vaccines administered concurrently with a fourth dose of heptavalent pneumococcal conjugate vaccine compared with the vaccines administered without heptavalent pneumococcal conjugate vaccine.
    Black SB, Cimino CO, Hansen J, Lewis E, Ray P, Corsaro B, Graepel J, Laufer D.
    Pediatr Infect Dis J; 2006 Apr 13; 25(4):306-11. PubMed ID: 16567981
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
    Vesikari T, Karvonen A, Lindblad N, Korhonen T, Lommel P, Willems P, Dieussaert I, Schuerman L.
    Pediatr Infect Dis J; 2010 Jun 13; 29(6):e47-56. PubMed ID: 20508478
    [Abstract] [Full Text] [Related]

  • 20. Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine.
    Shinefield HR, Black S, Kuter BJ.
    J Infect Dis; 2008 Mar 01; 197 Suppl 2():S152-5. PubMed ID: 18419390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.